Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide).

Pramlintide, an adjunct treatment to mealtime insulin for patients with type 2 and type 1 diabetes, aids glycemic control by suppressing postprandial glucagon secretion, slowing gastric emptying, and enhancing satiety.

Who Took Part

The study group was 24 patients.

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, single-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

In this single-blind Amylin (Islet Amyloid Polypeptide) study one party knew the assignments and the other did not.

The comparison arm used a placebo, so changes seen with Amylin (Islet Amyloid Polypeptide) could be set against what happens without it.

In the crossover set-up each of the patients took both Amylin (Islet Amyloid Polypeptide) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Acetaminophen, Amyloid, Analgesics, Non-Narcotic, Area Under Curve, Diabetes Mellitus, Type 2, Drug Interactions and Gastric Emptying.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2007 (Journal of clinical pharmacology), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.